首页> 美国卫生研究院文献>Frontiers in Pharmacology >Pathway-Based Analysis of Genome-Wide Association Data Identified SNPs in HMMR as Biomarker for Chemotherapy- Induced Neutropenia in Breast Cancer Patients
【2h】

Pathway-Based Analysis of Genome-Wide Association Data Identified SNPs in HMMR as Biomarker for Chemotherapy- Induced Neutropenia in Breast Cancer Patients

机译:基于通路的全基因组关联数据鉴定的HMMR中SNP作为乳腺癌患者化疗引起的中性粒细胞减少的生物标志物

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Neutropenia secondary to chemotherapy in breast cancer patients can be life-threatening and there are no biomarkers available to predict the risk of drug-induced neutropenia in those patients. We previously performed a genome-wide association study (GWAS) for neutropenia events in women with breast cancer who were treated with 5-fluorouracil, epirubicin and cyclophosphamide and recruited to the SUCCESS-A trial. A genome-wide significant single-nucleotide polymorphism (SNP) signal in the tumor necrosis factor superfamily member 13B (TNFSF13B) gene, encoding the cytokine B-cell activating factor (BAFF), was identified in that GWAS. Taking advantage of these existing GWAS data, in the present study we utilized a pathway-based analysis approach by leveraging knowledge of the pharmacokinetics and pharmacodynamics of drugs and breast cancer pathophysiology to identify additional SNPs/genes associated with the underlying etiology of chemotherapy-induced neutropenia. We identified three SNPs in the hyaluronan mediated motility receptor (HMMR) gene that were significantly associated with neutropenia (p < 1.0E-04). Those three SNPs were trans-expression quantitative trait loci for the expression of TNFSF13B (p < 1.0E-04). The minor allele of these HMMR SNPs was associated with a decreased TNFSF13B mRNA level. Additional functional studies performed with lymphoblastoid cell lines (LCLs) demonstrated that LCLs possessing the minor allele for the HMMR SNPs were more sensitive to drug treatment. Knock-down of TNFSF13B in LCLs and HL-60 promyelocytic cells and treatment of those cells with BAFF modulated the cell sensitivity to chemotherapy treatment. These results demonstrate that HMMR SNP-dependent cytotoxicity of these chemotherapeutic agents might be related to TNFSF13B expression level. In summary, utilizing a pathway-based approach for the analysis of GWAS data, we identified additional SNPs in the HMMR gene that were associated with neutropenia and also were correlated with TNFSF13B expression.
机译:乳腺癌患者继发于化疗的中性粒细胞减少症可能危及生命,并且尚无生物标志物可预测这些患者药物性中性粒细胞减少症的风险。我们先前针对乳腺癌妇女中性粒细胞减少症事件进行了全基因组关联研究(GWAS),这些妇女接受了5-氟尿嘧啶,表柔比星和环磷酰胺的治疗,并被招募到SUCCESS-A试验中。在该GWAS中鉴定出了肿瘤坏死因子超家族成员13B(TNFSF13B)基因中的全基因组显着单核苷酸多态性(SNP)信号,该基因编码细胞因子B细胞激活因子(BAFF)。利用这些现有的GWAS数据,在本研究中,我们利用基于药物的药代动力学和药效学知识以及乳腺癌病理生理学的知识,利用基于途径的分析方法来鉴定与化学性中性粒细胞减少症的潜在病因相关的其他SNP /基因。 。我们在透明质酸介导的运动受体(HMMR)基因中发现了三个与中性粒细胞减少症显着相关的SNP(p <1.0E-04)。这三个SNP是TNFSF13B表达的反式表达数量性状基因座(p <1.0E-04)。这些HMMR SNP的次要等位基因与TNFSF13B mRNA水平降低有关。用淋巴母细胞样细胞系(LCL)进行的其他功能研究表明,对于HMMR SNP具有较小等位基因的LCL对药物治疗更为敏感。敲低LCL和HL-60早幼粒细胞中的TNFSF13B并用BAFF处理这些细胞可调节细胞对化疗的敏感性。这些结果表明,这些化疗药物的HMMR SNP依赖性细胞毒性可能与TNFSF13B表达水平有关。总之,利用基于途径的方法来分析GWAS数据,我们在HMMR基因中发现了与中性粒细胞减少症相关并与TNFSF13B表达相关的其他SNP。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号